In order to examine the possible role of WT1 gene overexpression in assessing treatment response, prognosis and survival of AML patients with normal cytogenetics, All CN-AML patients were divided into three different risk subgroups based on their known molecular abnormalities such as the FLT3 and NPM1 gene mutation statuses. Here, NPM1 is linked to acute myeloid leukemia.